Sientra settles lawsuits over public offering
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Inogen sales, profits soar in third quarter
Inogen revenues, profits and earnings per share were up for the third quarter, the company announced Nov. 3. Inogen, a Goleta-based manufacturer of direct-to-consumer respiratory products, said revenues increased 33 percent during the quarter from $40.7 million during the same quarter last year to $54.4 million in 2016, which topped analyst revenue estimates of $47.9 Read More →
Amgen beats analysts’ revenue, earnings per share estimates
Amgen revenues increased 2 percent during the third quarter as it beat analysts’ revenue and earnings per share estimates thanks to cost-cutting measures and lower research measures. Revenues for the Thousand Oaks-based biotech giant increased from $5.72 billion during the third quarter of 2015 to $5.81 billion in 2016, which beat analyst estimates of $5.73 Read More →
Sientra CFO resigns, new CFO named
Embattled-breast implant manufacturer Sientra said in a news release Oct. 27 that Chief Financial Officer Matthew Pigeon stepped down from his position “to pursue other opportunities.” Patrick Williams, who most recently served as CFO of Pleasanton-based ZELTIQ Aesthetics from November 2012 until this past April, will fill Pigeon’s roll as CFO at Sientra. Williams also Read More →
Dignity Health plans merger with Catholic Health Initiatives
San Francisco-based Dignity Health plans to merge with Colorado-based Catholic Health Initiatives in a deal that would combine a couple of the largest nonprofit providers in the country, Dignity announced on Oct. 24. Dignity Health owns five hospitals in the Tri-Counties, including Arroyo Grande Community Hospital, French Hospital Medical Center in San Luis Obispo, St. Read More →
Proposition 61 will not cure sky high drug prices
Proposition 61 goes before California voters in just a few weeks. And as the Business Times reported on Oct. 14, Amgen, the Thousand Oaks-based biotech giant, along with other major drug companies, is spending millions to oppose Proposition 61 and its plan to control drug prices. Proponents promote the David vs. Goliath aspect of their Read More →